ATE448797T1 - Zusammensetzung enthaltend il-1ra als interleukin-1 inhibitor und hyaluronan als polymer mit verzögerter wirkstofffreigabe - Google Patents
Zusammensetzung enthaltend il-1ra als interleukin-1 inhibitor und hyaluronan als polymer mit verzögerter wirkstofffreigabeInfo
- Publication number
- ATE448797T1 ATE448797T1 AT97906551T AT97906551T ATE448797T1 AT E448797 T1 ATE448797 T1 AT E448797T1 AT 97906551 T AT97906551 T AT 97906551T AT 97906551 T AT97906551 T AT 97906551T AT E448797 T1 ATE448797 T1 AT E448797T1
- Authority
- AT
- Austria
- Prior art keywords
- release polymer
- hyaluronan
- interleukin
- delayed
- inhibitor
- Prior art date
Links
- 102000000589 Interleukin-1 Human genes 0.000 title abstract 2
- 108010002352 Interleukin-1 Proteins 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 229920000642 polymer Polymers 0.000 title abstract 2
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 title 1
- 229940099552 hyaluronan Drugs 0.000 title 1
- 229920002674 hyaluronan Polymers 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 102000009634 interleukin-1 receptor antagonist activity proteins Human genes 0.000 abstract 1
- 108040001669 interleukin-1 receptor antagonist activity proteins Proteins 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1141996P | 1996-02-09 | 1996-02-09 | |
| US3278996P | 1996-12-06 | 1996-12-06 | |
| US3624197P | 1997-01-23 | 1997-01-23 | |
| US08/798,414 US6096728A (en) | 1996-02-09 | 1997-02-07 | Composition and method for treating inflammatory diseases |
| PCT/US1997/002131 WO1997028828A1 (en) | 1996-02-09 | 1997-02-10 | Composition comprising interleukin-1 inhibitor and controlled release polymer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE448797T1 true ATE448797T1 (de) | 2009-12-15 |
Family
ID=27486083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97906551T ATE448797T1 (de) | 1996-02-09 | 1997-02-10 | Zusammensetzung enthaltend il-1ra als interleukin-1 inhibitor und hyaluronan als polymer mit verzögerter wirkstofffreigabe |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0904112B1 (de) |
| JP (2) | JP4344404B2 (de) |
| KR (1) | KR20040010739A (de) |
| CN (1) | CN1215340A (de) |
| AT (1) | ATE448797T1 (de) |
| AU (1) | AU724960C (de) |
| BR (1) | BR9707325A (de) |
| CA (2) | CA2539273C (de) |
| CZ (1) | CZ299025B6 (de) |
| DE (1) | DE69739656D1 (de) |
| EA (2) | EA001792B1 (de) |
| ES (1) | ES2334726T3 (de) |
| HU (1) | HU230160B1 (de) |
| IL (1) | IL125552A0 (de) |
| MX (1) | MX9806191A (de) |
| NO (1) | NO983543L (de) |
| NZ (2) | NZ331163A (de) |
| SK (1) | SK288144B6 (de) |
| WO (1) | WO1997028828A1 (de) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998024477A1 (en) | 1996-12-06 | 1998-06-11 | Amgen Inc. | Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases |
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| DK2319928T3 (da) | 1998-10-23 | 2013-06-24 | Kirin Amgen Inc | Dimere trombopoietiske peptidomimetika, der binder til MPL-receptor og har trombopoietisk aktivitet |
| US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
| AT406054B (de) * | 1998-11-04 | 2000-02-25 | Andreas Bernkop-Schnuerch | Verfahren zur verbesserung der mucoadhäsion von polymeren sowie deren herstellung und verwendung |
| DK1203583T3 (da) * | 1999-06-21 | 2006-04-18 | Santen Pharmaceutical Co Ltd | Afhjælpende midler til arthrosis deformans |
| CN1402642A (zh) * | 1999-07-21 | 2003-03-12 | 奥默罗斯公司 | 用于抑制疼痛,炎症和软骨退化的溶液及方法 |
| US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
| CA2407956A1 (en) * | 2000-05-03 | 2001-11-08 | Amgen Inc. | Modified peptides as therapeutic agents |
| US7324635B2 (en) | 2000-05-04 | 2008-01-29 | Telemaze Llc | Branch calling and caller ID based call routing telephone features |
| US20010053764A1 (en) * | 2000-05-12 | 2001-12-20 | Sims John E. | Interleukin-1 inhibitors in the treatment of diseases |
| CA2423227C (en) | 2000-10-12 | 2011-11-29 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| US7087224B2 (en) | 2000-10-31 | 2006-08-08 | Amgen Inc. | Method of treating anemia by administering IL-1ra |
| JP4212470B2 (ja) | 2001-06-26 | 2009-01-21 | アムジェン フレモント インク． | Ｏｐｇｌへの抗体 |
| US6818613B2 (en) | 2001-11-07 | 2004-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | Aqueous sustained-release formulations of proteins |
| MXPA04006875A (es) * | 2002-01-18 | 2004-12-06 | Control Delivery Sys Inc | Sistema de gel polimerico para suministro controlado de cofarmacos. |
| JP4606161B2 (ja) | 2002-05-21 | 2011-01-05 | アムジエン・インコーポレーテツド | 置換複素環式化合物および使用方法 |
| KR101317045B1 (ko) | 2002-09-06 | 2013-10-16 | 암젠 인코포레이티드 | 치료학적 인체 항-ｉｌ-1ｒ1 모노클로날 항체 |
| US8273347B2 (en) | 2003-05-13 | 2012-09-25 | Depuy Spine, Inc. | Autologous treatment of degenerated disc with cells |
| US7429378B2 (en) | 2003-05-13 | 2008-09-30 | Depuy Spine, Inc. | Transdiscal administration of high affinity anti-MMP inhibitors |
| US7553827B2 (en) | 2003-08-13 | 2009-06-30 | Depuy Spine, Inc. | Transdiscal administration of cycline compounds |
| US7344716B2 (en) | 2003-05-13 | 2008-03-18 | Depuy Spine, Inc. | Transdiscal administration of specific inhibitors of pro-inflammatory cytokines |
| US8361467B2 (en) * | 2003-07-30 | 2013-01-29 | Depuy Spine, Inc. | Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints |
| US8895540B2 (en) | 2003-11-26 | 2014-11-25 | DePuy Synthes Products, LLC | Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
| RS57852B1 (sr) * | 2004-04-02 | 2018-12-31 | Swedish Orphan Biovitrum Ab Publ | Postupci za smanjenje agregacije il-1ra |
| ES2629397T3 (es) | 2004-09-24 | 2017-08-09 | Amgen Inc. | Moléculas de Fc modificadas |
| CA2590159C (en) * | 2004-12-30 | 2011-07-12 | Genzyme Corporation | Regimens for intra-articular viscosupplementation |
| EP1896072A4 (de) * | 2005-06-24 | 2013-01-09 | Univ Duke | System zur direkten heilmittelverabreichung auf der basis wärmegesteuerter biopolymere |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| PE20070684A1 (es) | 2005-11-14 | 2007-08-06 | Amgen Inc | MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP |
| US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
| GB0708376D0 (en) | 2007-05-01 | 2007-06-06 | Alligator Bioscience Ab | Novel polypeptides and uses thereof |
| CN101918018B (zh) | 2007-11-14 | 2012-12-05 | 再生医药有限公司 | 使用白介素-1受体拮抗剂作为骨髓保护剂的方法 |
| US8986696B2 (en) | 2007-12-21 | 2015-03-24 | Depuy Mitek, Inc. | Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints |
| US10106587B2 (en) | 2008-02-27 | 2018-10-23 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
| KR200451958Y1 (ko) * | 2008-10-09 | 2011-01-21 | (주)에이치시티 | 모바일기기용 카드형 안테나장치 |
| PE20120359A1 (es) | 2009-03-06 | 2012-04-13 | Genentech Inc | Formulacion con anticuerpo |
| US20110052561A1 (en) * | 2009-08-27 | 2011-03-03 | Biomet Biologics,LLC | Osteolysis treatment |
| TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
| CN101690801B (zh) | 2009-10-26 | 2012-08-01 | 上海交通大学 | 白细胞介素-1受体拮抗剂的用途及其药物组合物 |
| DE202009017772U1 (de) | 2009-12-10 | 2011-04-21 | Orthogen Ag | Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid |
| WO2012109373A2 (en) * | 2011-02-08 | 2012-08-16 | Abbott Laboratories | Treatment of osteoarthritis and pain |
| SI2672985T1 (sl) | 2011-02-11 | 2016-09-30 | Swedish Orphan Biovitrum Ab (Publ) | Farmacevtski sestavki, brez citrata, ki obsegajo anakinro |
| US20140234330A1 (en) | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
| US20140302131A1 (en) | 2011-09-02 | 2014-10-09 | Novozymes A/S | Oral formulations containing hyaluronic acid for sustained drug release |
| US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
| US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
| US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
| US9758806B2 (en) | 2013-03-15 | 2017-09-12 | Biomet Biologics, Llc | Acellular compositions for treating inflammatory disorders |
| US9878011B2 (en) | 2013-03-15 | 2018-01-30 | Biomet Biologics, Llc | Treatment of inflammatory respiratory disease using biological solutions |
| EP3054982B1 (de) * | 2013-10-08 | 2019-05-01 | Ascendis Pharma A/S | Hydrogel-konjugiertes il-1ra prodrug |
| US20160000936A1 (en) | 2014-06-10 | 2016-01-07 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
| CZ309295B6 (cs) * | 2015-03-09 | 2022-08-10 | Contipro A.S. | Samonosný, biodegradabilní film na bázi hydrofobizované kyseliny hyaluronové, způsob jeho přípravy a použití |
| US10041044B2 (en) | 2016-07-29 | 2018-08-07 | Trustees Of Boston University | Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development |
| CN110891611B (zh) | 2017-03-22 | 2024-03-29 | 阿森迪斯制药公司 | 水凝胶交联透明质酸前药组合物和方法 |
| CN112584823A (zh) * | 2018-06-22 | 2021-03-30 | 纽约哥伦比亚大学理事会 | 用于治疗颞颌关节退化的缓释组成物及方法 |
| WO2020035482A1 (en) | 2018-08-13 | 2020-02-20 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
| US12370240B2 (en) | 2018-11-28 | 2025-07-29 | Genascence Corporation | Methods and compositions for treating osteoarthritis |
| WO2021026289A1 (en) | 2019-08-08 | 2021-02-11 | Avidence Therapeutics, Inc. | Microsphere-Based Injectible Celecoxib Formulation |
| US20250283174A1 (en) | 2022-05-16 | 2025-09-11 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stem cells induced by chronic inflammation |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| AU631545B2 (en) | 1988-04-15 | 1992-12-03 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| EP0393438B1 (de) | 1989-04-21 | 2005-02-16 | Amgen Inc. | TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs |
| IL95031A (en) | 1989-07-18 | 2007-03-08 | Amgen Inc | Method for the production of a human recombinant tumor necrosis factor inhibitor |
| CA2485553A1 (en) | 1989-09-05 | 1991-03-21 | Immunex Corporation | Tumor necrosis factor - .alpha. and - .beta. receptors |
| AU649245B2 (en) * | 1990-04-02 | 1994-05-19 | Amgen, Inc. | Methods for treating interleukin-1 mediated diseases |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US6458360B1 (en) | 1990-04-25 | 2002-10-01 | The Johns Hopkins University | Soluble complement regulatory molecules |
| WO1991017184A1 (en) | 1990-04-27 | 1991-11-14 | The Upjohn Company | Modified interleukin-1 inhibitors |
| DK0575545T3 (da) | 1991-03-15 | 2003-09-15 | Amgen Inc | Pegylering af polypeptider |
| NO940913L (no) * | 1993-03-26 | 1994-09-27 | Bristol Myers Squibb Co | Preparater for kontrollert frigivelse av biologisk aktiv TGF- |
| JPH06321803A (ja) * | 1993-05-17 | 1994-11-22 | Kirin Brewery Co Ltd | 水溶性ペプチドホルモンの徐放性製剤 |
| US5385887A (en) * | 1993-09-10 | 1995-01-31 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
| WO1995010298A1 (en) * | 1993-10-12 | 1995-04-20 | Mary Lake Polan | Method of contraception |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| AU698393B2 (en) | 1994-06-24 | 1998-10-29 | Immunex Corporation | Controlled release polypeptide compositions and methods of treating inflammatory bowel disease |
| IT1269989B (it) | 1994-09-21 | 1997-04-16 | Dompe Spa | Antagonisti recettoriali di il-1 ad aumentata attivita' inibitoria |
-
1997
- 1997-02-10 WO PCT/US1997/002131 patent/WO1997028828A1/en not_active Ceased
- 1997-02-10 EA EA199800694A patent/EA001792B1/ru not_active IP Right Cessation
- 1997-02-10 DE DE69739656T patent/DE69739656D1/de not_active Expired - Lifetime
- 1997-02-10 EA EA200000825A patent/EA200000825A1/ru unknown
- 1997-02-10 AU AU21213/97A patent/AU724960C/en not_active Expired
- 1997-02-10 EP EP97906551A patent/EP0904112B1/de not_active Expired - Lifetime
- 1997-02-10 IL IL12555297A patent/IL125552A0/xx unknown
- 1997-02-10 CZ CZ0237398A patent/CZ299025B6/cs not_active IP Right Cessation
- 1997-02-10 CN CN97193632A patent/CN1215340A/zh active Pending
- 1997-02-10 NZ NZ331163A patent/NZ331163A/xx unknown
- 1997-02-10 AT AT97906551T patent/ATE448797T1/de not_active IP Right Cessation
- 1997-02-10 JP JP52874197A patent/JP4344404B2/ja not_active Expired - Lifetime
- 1997-02-10 HU HU9902612A patent/HU230160B1/hu unknown
- 1997-02-10 CA CA2539273A patent/CA2539273C/en not_active Expired - Lifetime
- 1997-02-10 NZ NZ503548A patent/NZ503548A/en unknown
- 1997-02-10 KR KR10-2003-7016565A patent/KR20040010739A/ko not_active Ceased
- 1997-02-10 CA CA002244664A patent/CA2244664C/en not_active Expired - Lifetime
- 1997-02-10 BR BR9707325A patent/BR9707325A/pt not_active Application Discontinuation
- 1997-02-10 SK SK1036-98A patent/SK288144B6/sk not_active IP Right Cessation
- 1997-02-10 ES ES97906551T patent/ES2334726T3/es not_active Expired - Lifetime
-
1998
- 1998-07-31 MX MX9806191A patent/MX9806191A/es active IP Right Grant
- 1998-07-31 NO NO983543A patent/NO983543L/no not_active Application Discontinuation
-
2007
- 2007-05-22 JP JP2007136048A patent/JP2007211027A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CZ299025B6 (cs) | 2008-04-02 |
| EP0904112A1 (de) | 1999-03-31 |
| JP2007211027A (ja) | 2007-08-23 |
| AU724960B2 (en) | 2000-10-05 |
| EA200000825A1 (ru) | 2001-02-26 |
| EP0904112B1 (de) | 2009-11-18 |
| NZ503548A (en) | 2001-09-28 |
| ES2334726T3 (es) | 2010-03-15 |
| SK103698A3 (en) | 2001-01-18 |
| AU2121397A (en) | 1997-08-28 |
| KR20040010739A (ko) | 2004-01-31 |
| EA001792B1 (ru) | 2001-08-27 |
| CA2244664C (en) | 2008-06-03 |
| AU724960C (en) | 2002-08-15 |
| JP2001500472A (ja) | 2001-01-16 |
| IL125552A0 (en) | 1999-03-12 |
| SK288144B6 (sk) | 2013-12-02 |
| NO983543L (no) | 1998-10-08 |
| DE69739656D1 (de) | 2009-12-31 |
| MX9806191A (es) | 1998-10-31 |
| BR9707325A (pt) | 1999-04-13 |
| HUP9902612A3 (en) | 2001-11-28 |
| JP4344404B2 (ja) | 2009-10-14 |
| CA2244664A1 (en) | 1997-08-14 |
| HUP9902612A2 (hu) | 1999-11-29 |
| HU230160B1 (hu) | 2015-09-28 |
| NZ331163A (en) | 2000-07-28 |
| EA199800694A1 (ru) | 1999-02-25 |
| NO983543D0 (no) | 1998-07-31 |
| CN1215340A (zh) | 1999-04-28 |
| CA2539273A1 (en) | 1997-08-14 |
| WO1997028828A1 (en) | 1997-08-14 |
| CA2539273C (en) | 2014-02-04 |
| CZ237398A3 (cs) | 1999-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE448797T1 (de) | Zusammensetzung enthaltend il-1ra als interleukin-1 inhibitor und hyaluronan als polymer mit verzögerter wirkstofffreigabe | |
| BRPI9908182B8 (pt) | composições de proteína de matriz para cura de feridas | |
| FI973292A7 (fi) | Substituoituja isoksatsoleja tulehduksen hoitamiseksi | |
| BR9710372A (pt) | Composto composi-Æo farmac-utica e processos para o tratamento de uma doen-a inflamatÄria e de doen-as mediadas pela cliclooxigenase | |
| DK0995747T3 (da) | Substituterede sulfonylphenylheterocykler som cyclooxygenase-2- og 5-lipoxygenase-inhibitorer | |
| WO1998024427A3 (en) | Compositions and methods for treating or preventing inflammatory diseases | |
| WO1999062510A3 (en) | Compositions comprising anti-microtubule agents for treating or preventing inflammatory diseases | |
| ATE88346T1 (de) | Zusammensetzung mit gehalt an einem nichtsteroiden entzuendungshemmenden mittel und einem nichtbakterizidwirksamen tetracyclin. | |
| NO981392D0 (no) | Substituerte pyrazolylbenzensulfonamider for anvendelse i veterinærterapi som antiinflammatorisk middel | |
| BR9908182A (pt) | Composições de proteìna de matriz para cura deferidas | |
| FI972308A0 (fi) | 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi | |
| SE9604751D0 (sv) | New therapy | |
| DK0912185T3 (da) | Nye farmaceutiske sammensætninger indeholdende steroidnitratesterderivater, der kan anvendes som antiinflammatoriske lægemidler | |
| DK0782441T3 (da) | Farmaceutisk kontrol af inflammation | |
| BR0308957A (pt) | Composto, composição farmacêutica, método para o tratamento de uma inflamação ou de uma desordem associada a uma inflamação em um paciente, uso dos compostos e processo para sua preparação | |
| PT900563E (pt) | Producao de formulacoes farmaceuticas para o tratamento de edema e doencas venosas | |
| BG101126A (en) | The use of muramylpeptide compounds | |
| BR9610211A (pt) | Composições farmacêuticas baseadas em gel tipo gliceril poli(meta)acrilato | |
| DK0951294T3 (da) | Sårhelende formuleringer indeholdende humanplasmafibronectin | |
| NO20031650D0 (no) | Nye legemidler for leversykdommer | |
| FR2718024B1 (fr) | Médicament et composition pharmaceutique pour le traitement de l'inflammation. | |
| ATE189395T1 (de) | Verwendung von protease nexin-i als mittel gegen entzündungen | |
| PT841933E (pt) | Composicoes do inibidor bowman-birk para tratamento de doencas inflamatorias | |
| FI950649A7 (fi) | Substituoidut sykloheksanoliesterit, niiden käyttö sairauksien hoitamiseksi ja farmaseuttiset valmisteet | |
| ATE232738T1 (de) | Kolostrum enthaltende pharmazeutische zusammensetzungen und deren verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |